Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

10 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

WTZ-GIST-09-01 (Imatinib + LBH589) Final Medical Examination 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Final Medical Examination 2009-011417-24

- 02/12/2016 - 1 Formulário, 1 Grupo de itens, 16 Elementos de dados, 1 Idioma
Grupo de itens: Final medical examination
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Additional Cycle 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Additional Cycle 2009-011417-24

- 01/12/2016 - 1 Formulário, 2 Grupos de itens, 16 Elementos de dados, 1 Idioma
Grupos de itens: Chemotherapy Regimen, Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 2 Week 9 (V10) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 2 Week 9 (V10) 2009-011417-24

- 23/11/2016 - 1 Formulário, 1 Grupo de itens, 16 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 2 Week 8 (V9) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 2 Week 8 (V9) 2009-011417-24

- 23/11/2016 - 1 Formulário, 1 Grupo de itens, 15 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 2 Week 7 (V8) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 2 Week 7 (V8) 2009-011417-24

- 23/11/2016 - 1 Formulário, 1 Grupo de itens, 15 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 2 Week 6 (V7) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 2 Week 6 (V7) 2009-011417-24

- 23/11/2016 - 1 Formulário, 1 Grupo de itens, 16 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 4 (V5) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 4 (V5) 2009-011417-24

- 23/11/2016 - 1 Formulário, 1 Grupo de itens, 15 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 5 (V6) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 5 (V6) 2009-011417-24

- 23/11/2016 - 1 Formulário, 1 Grupo de itens, 16 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 2 (V3) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 2 (V3) 2009-011417-24

- 23/11/2016 - 1 Formulário, 1 Grupo de itens, 17 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 3 (V4) 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Cycle 1 Week 3 (V4) 2009-011417-24

- 23/11/2016 - 1 Formulário, 1 Grupo de itens, 15 Elementos de dados, 1 Idioma
Grupo de itens: Vital signs
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial